Drug Trial Radar · NCT05795140
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
May 8, 2024
Primary completion
Jul 16, 2032
Study completion Jul 27, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
Conditions
- Atypical Hemolytic Uremic Syndrome
Interventions
Iptcaopan 200 mgDrug
Open label, participant specific kits, hard gelatin capsules to be taken twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events and serious adverse eventsTime frame: Throughout the study duration, up to 4 years
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Rio de Janeiro, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Ostrava, Poruba, Czechia · Recruiting
Novartis Investigative Site
Nagpur, Maharashtra, India · Active not recruiting
Novartis Investigative Site
Pune, Maharashtra, India · Recruiting
Novartis Investigative Site
Iruma-gun, Saitama, Japan · Recruiting
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye) · Recruiting
Novartis Investigative Site
Mersin, Yenisehir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.